Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ACOSOG-Z4099||ACSOG||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br>||Adult CIRB - Late Phase Emphasis||Completed|
|ARET0332||COG||A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study||Pediatric CIRB||Completed|
|ADVL0524||COG||Phase II Trial of Ixabepilone (BMS-247550); an Epothilone B Analog; in Children and Young Adults with Refractory Solid Tumors||Pediatric CIRB||Completed|
|S0334||SWOG||Myeloma Specimen Repository Protocol Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|S1300||SWOG||A Randomized; Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systematically After Previous Clinical Benefit From Crizotinib Monotherapy<br>||Adult CIRB - Early Phase Emphasis||Completed|
|CALGB-10701||CALGB||A Phase II Study of Dasatinib (Sprycel) (IND #73969; NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB; ECOG and SWOG||Adult CIRB - Late Phase Emphasis||Completed|
|ACCL05C1||COG||A Group-Wide; Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy||Pediatric CIRB||Completed|
|EAQ152||ECOG-ACRIN||A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling||Adult CIRB - Early Phase Emphasis||Completed|
|CALGB-80203||CALGB||A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum||Adult CIRB - Late Phase Emphasis||Completed|
|S0106||SWOG||A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Completed|